VivoSeq
Immunology

Myasthenia Gravis

85

Pipeline Programs↗

64

Active Trials↗

45

Companies Involved↗

Myasthenia Gravis is a moderately active landscape with 85 programs across 45 companies. The most active players are Candid Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Guangdong ProCapZoom Biosciences Co., Ltd.. 4 therapies are approved with 32 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

48/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Candid Therapeutics

1 program

Phase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1 program

Phase 1G

Guangdong ProCapZoom Biosciences Co., Ltd.

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

64 of 94 classified programs — the dominant modality here.

32%ALL OTHERSMonoclonal antibody1516%Cell therapy1011%Protein / enzyme44%RNA therapy11%

Small molecule leads; the ring shows all 94 classified programs, each share of the total. Modality classified for 98% of 103 pipeline programs.

Analysis

Trial Status

143

clinical trials

Completed53 · 37%
Recruiting39 · 27%
Not yet recruiting14 · 10%
Terminated13 · 9%
Unknown status10 · 7%
Active, not recruiting10 · 7%
Other4 · 3%

Clinical Trials

Trial Activity

143 trials

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Recruiting·—·Phase 3·NCT06765161·30 enrolled
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Recruiting·CCartesian Therapeutics·Phase 3·NCT06799247·100 enrolled
A Prospective Cohort Study of Myasthenia Gravis in China
Recruiting·PPeking Union Medical College Hospital·N/A·NCT06006832·202 enrolled
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06688435·50 enrolled
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT07413835·6 enrolled
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Recruiting·Argenx logoArgenx·Phase 2/3·NCT06392386·12 enrolled
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
Recruiting·Argenx logoArgenx·Phase 4·NCT06909214·30 enrolled
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT06860633·20 enrolled
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Recruiting·VVor Biopharma·Phase 3·NCT06456580·180 enrolled
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06909253·50 enrolled
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04951622·199 enrolled
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Recruiting·TTing Chang, MD·Phase 1·NCT06371040·9 enrolled
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Recruiting·CCandid Therapeutics·Phase 1·NCT07215650·44 enrolled
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Recruiting·TTang-Du Hospital·Phase 2·NCT05067348·64 enrolled
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Recruiting·—·Phase 1·NCT07058298·6 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)